Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Renal Cell 63Carcinoma, Hepatocellular 25Prostatic Neoplasms 21Neoplasm Metastasis 19Neoplasms 17Carcinoma, Non-Small-Cell Lung 16Kidney Neoplasms 14Osteosarcoma 9Neuroendocrine Tumors 9Carcinoma, Transitional Cell 9Sarcoma 8Colorectal Neoplasms 8Carcinoma, Medullary 8Urinary Bladder Neoplasms 7Sarcoma, Ewing 7Melanoma 7Breast Neoplasms 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Recurrence 5Pancreatic Neoplasms 5Lung Neoplasms 5Carcinoma 5Urethral Neoplasms 4Triple Negative Breast Neoplasms 4Multiple Myeloma 4Thyroid Cancer, Papillary 3Small Cell Lung Carcinoma 3

Interventions

Imatinib Mesylate 3mirdametinib 2tipifarnib 1talimogene laherparepvec 1pirfenidone 1nilotinib 1emvododstat 1diphenylcyclopropenone 1cabozantinib 1binimetinib 1Sunitinib 1Sirolimus 1Sevoflurane 1Propofol 1Percutaneous Collagen Induction 1Nitrous Oxide 1Magnetic Resonance Spectroscopy 1Lidocaine 1Lasers, Solid-State 1Lasers 1Glycopyrrolate 1Dexmedetomidine 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurofibromatoses × cabozantinib × Clear all
NCT02101736 2023-05-24

NF105-CABO

University of Alabama at Birmingham

Phase 2 Completed
45 enrolled 10 charts
CNS

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon âš¡